MGI Pharma and MethylGene cancer deal

MOGN gained a North American license from MethylGene (Montreal, Quebec) to MG98, an mRNA inhibitor, and other small molecule inhibitors of DNA methyltransferase, to treat cancer. MOGN will make an equ...